about
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. ...
Read More
47.49
-4.38
(-8.44%)
12.5M
XNAS Volume
XNAS 23 Jan, 2026 1:45 PM (EST)
Regulatory Headwinds
Moderna to curb investments in vaccine trials amid health officials' opposition to immunizations
See details
Low Financial Strength
Expensive Valuation
Technically Bullish
Momentum Trap
These stocks have weak financials and expensive valuation. Buying interest may quickly dissipate. Investors should exercise caution
View Similar
Embed DVM
Moderna Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..